Gene therapy developers REGENXBIO ( RGNX -11% ) and Adverum Biotechnologies ( ADVM +17.4% ) have diverged after data presentations on their respective gene therapy candidates for wet age-related macular degeneration (wet AMD) at the American Academy of Ophthalmology Annual Meeting in San...

-- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with  median follow up of 34 weeks -- -- Sequential enrollment planned for OPTIC third and fourth cohorts -- -- Company to host and webcast a discussion with key opinion leaders on  Saturd...

It's almost time for the American Academy of Opthalmology's (AAO) annual meeting again, and this year's event will contain some high-stakes presentations. This year, all three of these biopharmaceutical companies will present clinical trial results that could send their stock prices soaring -- o...